Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
melanoma
Biotech
Pfizer drops another early cancer candidate from Seagen
The decision to scrap the ADC was made for “business reasons” and “was not related to any safety concerns or requests from regulatory authorities.”
Darren Incorvaia
Mar 19, 2026 12:56pm
After R&D head exits, Immunocore CEO pairs ambition with caution
Feb 13, 2026 12:44pm
Merck, Moderna sustain 49% melanoma risk reduction at 5 years
Jan 20, 2026 8:50am
Replimune's stock spikes 100% on FDA acceptance of resubmission
Oct 20, 2025 5:33pm
BioNTech fades cancer vax in late-stage melanoma setting
Oct 20, 2025 3:01pm
Evaxion stock slips on phase 2 cancer vax data
Oct 17, 2025 2:07pm
